KLRK1 and cancer: TGFβ downregulates the expression of NKG2D on NK cells and CD8+ T cells in several cancer models [105,106,107,109], and has been shown to suppress IL-15 and STAT5-mediated NK cell activation through the blockade of mTOR activation [110].